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OBJECTIVES We report our experience of percutaneous valve insertion in pulmonary position in humans.
BACKGROUND Over the past 40 years, prosthetic conduits have been developed to surgically establish
continuity between the right ventricle and the pulmonary artery. However, stenosis and
insufficiency of the conduit due to valvular degeneration or panus ingrowth frequently occur,
limiting patients’ lifespan. Percutaneous stenting of conduits has recently emerged as a
technique for delaying surgical replacement, but it creates a pulmonary regurgitation when
crossing the valve.
METHODS Seven children and one adult with stenosis and/or insufficiency of the pulmonary graft
underwent percutaneous implantation of a bovine jugular valve in pulmonary position.
RESULTS Percutaneous pulmonary valve (PV) replacement was successful in all patients. No compli-
cations occurred in early follow-up. Angiography, hemodynamic studies and echocardiogra-
phy after the procedure showed no significant regurgitation of the implanted valve.
Implantation was effective in relieving the obstruction in five patients. All patients showed
improvement in their clinical status at the latest follow-up (mean 10.1 months).
CONCLUSIONS Non-surgical insertion of the PV is possible without any major complications. This new
technique may have an important role in the management of conduit obstructions and
pulmonary regurgitation. (J Am Coll Cardiol 2002;39:1664–9) © 2002 by the American
College of Cardiology Foundation
Pulmonary valve (PV) regurgitation is generally considered
to be well tolerated by patients and therefore is clinically not
very important. However, over the past decade it has
become apparent that this may not be the case. Patients who
develop progressive pulmonary regurgitation after opera-
tions such as correction of tetralogy of Fallot or complex
pulmonary atresia may be prone to persistent pulmonary
regurgitation immediately after surgery if a valveless conduit
is involved or to progressive pulmonary regurgitation if a
valved conduit has been used. Progressively increasing
pulmonary regurgitation increases susceptibility to arrhyth-
mias, sudden death and right ventricular (RV) dysfunction
(1,2). There is no consensus on the timing of PV replace-
ment in this clinical situation. It is possible that if the PV is
replaced early enough, the RV dilation and dysfunction may
be reversible (3,4). Even so, replacement of the regurgitant
PV has not consistently produced recovery of the RV
function (5). This may be related to irreversible myocardial
damage already present before the valve surgery, aggravated
by cardiopulmonary bypass. A non-surgical and therefore
less traumatic technique of replacing the regurgitant PV
may have important advantages. The purpose of this article
is to report our early experience of percutaneous PV im-
plantation in humans.
PATIENTS AND METHODS
Eight patients—seven children and one adult—with signif-
icant pulmonary regurgitation and/or RV outflow tract
obstruction were included in the study protocol. The Ethics
Committee (CCPPRB, COCHIN, Paris, France) approved
the procedure of percutaneous PV insertion. Fully informed
consent was obtained from the parents when the patient was
a child and from the patient if the patient was an adult.
The seven children ranged in age between 10 and 17
years, mean of 12.14  2.3 years. One patient was previ-
ously reported (6). The details of all the patients are
included in Table 1. Three of the children had previously
had surgical repair of pulmonary atresia with ventricular
septal defect (VSD), three had previously had repair of
tetralogy of Fallot, and the seventh had an absent PV
syndrome. The initial palliation included one or more
systemic-to-pulmonary artery (PA) shunts in six of eight
patients, followed by a complete repair that consisted of
closing the VSD and inserting a prosthetic conduit between
the RV and the PA. Most of the children underwent
reoperation for replacement of the initial conduit with a
larger one during infancy.
The adult patient (age 38 years) had undergone repair of
tetralogy of Fallot at three years of age, followed by two
reoperations to replace the PV 15 and 25 years after the
original repair.
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All patients were symptomatic, with effort intolerance
and breathlessness, and needed conduit replacement because
of significant stenosis and/or pulmonary regurgitation. Be-
fore the procedure, six patients were in New York Heart
Association (NYHA) class II, and two were in NYHA class
III with cardiomegaly, moderate-to-severe RV dilation and
dysfunction on echocardiography.
Percutaneous replacement of the PV. In all the patients,
cardiac catheterization and hemodynamic evaluation were
performed, and angiograms were performed in multiple
projections in order to locate the position of the stenosis of
the PA or its branches and to define precisely the anatomy
of the RV outflow tract.
All the procedures were performed under general anes-
thesia. Cardiac catheterization was performed via the right
femoral vein percutaneously. Heparin (100 U/kg) and anti-
biotics (cephalosporins) were given intravenously at the
beginning of the procedure according to standard protocol.
After placement of a right coronary catheter in a distal
branch PA, a super-stiff exchange guide wire (Amplatz,
Meditech, Watertown, Massachusetts) was positioned in
the distal PA. This was followed by a manual inflation of a
balloon (Zmed II 18x4, Numed Inc., Nicholville, New
York) in the RV outflow tract to determine whether there
was sufficient room to implant a PV without creating
additional obstruction and to see that the stent could be
dilated to its maximum required diameter, especially in
those patients who already had some stenosis of the previous
surgically implanted valve. Moreover, when distal branch
pulmonary arterial stenosis was identified, this was dilated
first with an appropriate-sized balloon.
An 18-mm biological valve (Venpro), sutured into a
platinum stent (Numed Inc.) as previously described (7),
was manually crimped onto a delivery system consisting of a
balloon-in-balloon catheter. The valve/stent/balloon assem-
bly was frontloaded in an 18-F or 20-F sheath (Numed
Inc.). Thereafter, the stent/balloon assembly was withdrawn
fully into a protective sheath on the delivery system. The
whole assembly was then passed over the guide wire and
advanced into the PA. Once in an acceptable position, the
sheath covering the stent was withdrawn to expose the stent
crimped on the balloon. The inner balloon was initially
inflated followed by the outer balloon, thus deploying the
valved stent. The inner and the outer balloons were then
rapidly deflated, and the balloon catheter was removed from
the patient, leaving the guide wire still in place. Angio-
Abbreviations and Acronyms
NYHA  New York Heart Association
PA  pulmonary artery
PV  pulmonary valve
RV  right ventricle, right ventricular
VSD  ventricular septal defect
Table 1. Patient Characteristics
Patients
Age/Weight
(years/kg)
Congenital
Heart Defect Previous Surgery
1 12/45 PAVSD 1. central Blalock Taussig shunt at 10 days
2. right Blalock Taussig shunt at 10 months
3. total repair at 4.1 years
2 12/25 PAVSD 1. right Blalock Taussig shunt at 1 month
2. opening of the RVOT with a 6-mm nonvalved
Dacron conduit at 1.2 years
3. total repair with a valved conduit implantation at 2.2
years
4. conduit replacement at 7.5 years
3 10/30 PAVSD 1. right Blalock Taussig shunt at 10 days
2. left Blalock Taussig shunt at 16 months
3. central Blalock Taussig shunt at 4.7 years
4. total repair at 5.4 years
4 11/34 TOF 1. total repair with a Dacron enlargement of RVOT at
2 months
2. conduit placement at 6 months
3. conduit replacement at 5 years
5 38/66 TOF 1. total repair at 3 years
2. pulmonary valve implantation at 18 years
3. pulmonary valve replacement at 28 years
6 12/38 absent pulmonary
valve syndrome
1. total repair at 2 months
2. conduit replacement at 20 months
3. conduit replacement at 7 years
7 17/80 TOF 1. central Blalock Taussig shunt at 2 months
2. right Blalock Taussig at 10 months
3. total repair at 5 years
8 11/26 TOF 1. total repair at 13 months
2. conduit placement at 4 years
PAVSD pulmonary atresia with ventricular septal defect; RVOT right ventricular outflow tract; TOF tetralogy of Fallot.
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graphic and hemodynamic evaluation were repeated before
the guide wire was finally removed through a right coronary
catheter.
Follow-up. After discharge, each patient was seen at reg-
ular intervals for clinical evaluation, including physical
examination, 12-lead electrocardiography and chest X-ray,
and to evaluate the competence of the implanted valve by
cross-sectional and color Doppler echocardiography.
Early results. Right ventricular angiography before valve/
stent implantation showed severe calcification in the previ-
ous valved conduit in Patients 1, 3, 5 and 8. In Patients 2
and 4, the stenosis was located at the bifurcation of the PA
and at the insertion of the conduit into the RV respectively.
Patients 2 and 4 had dilation of branch PA stenosis before
the valve/stent implantation. Patient 3 had a severe stenosis
of the left PA with multiple pulmonary stenosis distally. In
Patients 6 and 7, the stenosis was located in the area of the
valve.
The results of the hemodynamic studies are summarized
in Table 2. The valve/stent was successfully implanted in all
eight patients. Immediately after implantation, the hemo-
dynamic and angiographic evaluation confirmed compe-
tence of the newly implanted valve in six patients (Fig. 1). In
Patient 4, the stent/valve/delivery system completely ob-
structed the right outflow tract before the deployment of the
valved stent during the placement of the device. This
Table 2. Hemodynamic Results and Doppler Gradient at the Last Follow-Up
Patients Conduit or Valve Type
Systolic Pressure Ratio Between Right
Ventricle and Aorta
(RV Peak Systolic Pressure)
Pulmonary Artery
Pressures Distal
to Conduit
(Systolic/Diastolic/Mean) Doppler Gradient
at Last Follow-Up
(m/2)Before After Before After
1 18-mm Carpentier-Edward valved
conduit
85% (80 mm Hg) 66% (50 mm Hg) 30/8/16 30/16/20 3
2 18-mm GoreTex non-valved
conduit
71% (70 mm Hg) 33% (40 mm Hg) 22/6/16 28/14/20 3
3 18-mm Hancock valved conduit 71% (65 mm Hg) 33% (40 mm Hg) 25/8/15 30/14/18 3
4 RVOT reconstruction with
Dacron patch
70% (90 mm Hg) 60% (50 mm Hg) 60/10/18 40/10/22 3.3
5 27-mm Hancock valve 33% (35 mm Hg) 33% (32 mm Hg) 28/12/16 32/16/20 2
6 16-mm Carpentier-Edward valved
conduit
90% (95 mm Hg) 50% (54 mm Hg) 31/8/15 32/14/19 3
7 20-mm Hancock valved conduit 85% (85 mm Hg) 60% (55 mm Hg) 30/8/16 30/16/20 3.5
8 18-mm Carpentier-Edward valved
conduit
90% (72 mm Hg) 38% (32 mm Hg) 28/16/20 16/8/20 2.5
RV  right ventricular; RVOT  right ventricular outflow tract.
Figure 1. Pulmonary angiograms: (left) pulmonary regurgitation, (right) valvular competence of the newly implanted valve.
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resulted in sudden deterioration with hypotension and
severe cyanosis, forcing us to react rapidly. Because we
supposed that the valved stent was correctly positioned, we
decided to deliver rather than pulling back the device in the
RV. Unfortunately, the valve was deployed slightly lower
than intended, lying a bit in the infundibulum. In Patients
4 and 5, an insignificant paraprosthetic regurgitation could
be visualized because of suboptimal positioning of the
valved stent. The relief of the conduit obstruction was
partial in Patients 1, 4 and 7.
The fluoroscopy time ranged from 28 to 129 min with a
mean at 52 min. The time for the procedure of valve/stent
implantation improved significantly after the first two cases.
Three patients developed pyrexia after the procedure. The
pyrexia lasted for 24 h and resolved spontaneously. No
evidence of infection was found in these patients.
All the patients were discharged between one and five
days after the procedure with aspirin at low dose. Echocar-
diography immediately before discharge confirmed compe-
tence of the implanted valve in all patients (Fig. 2). The
slight paraprosthetic leak in Patients 4 and 5 disappeared on
color Doppler echocardiography.
Follow-up. At the latest follow-up, ranging from five to 16
months (mean 10.1 months), all the patients had subjective
improvement of their symptoms, and color Doppler echo-
cardiography showed a fully competent PV. A reduction of
RV size and an improvement of systolic function of the RV
were suspected on transthoracic echocardiography evalua-
tion. In the adult patient, there was progressive improve-
ment of the RV function after the implantation, with
reduction in the dilation of the RV. Echocardiography also
showed that there was persistent elevation of the RV systolic
pressure because of partial relief of the conduit obstruction
in Patients 1, 3, 4 and 7. The systolic RV pressure tended to
be lower echographically during the follow-up compared
with the pressure just after the implantation (Table 2). Six
patients were in NYHA class I, and the remaining two
patients were in class II.
No stent migration occurred. Two stents showed a single
fracture of a weld between the wires, which was probably
due to difficulties at the time of passing the stent/valve
assembly through the skin. There were no clinical sequelae
from this.
DISCUSSION
Prosthetic valved or valveless conduits have been used
surgically to establish continuity between the RV and the
PA during complete repair of some congenital heart defects,
such as pulmonary atresia associated with a VSD or in some
patients with the tetralogy of Fallot. Over the past 40 years,
these prosthetic conduits have included valveless conduits
(8) and conduits with xenograft (9–14) or homograft valves
(15,16), pericardial valves (17) and mechanical valves (18).
Despite major advances in terms of durability, the lifespan
of prosthetic conduits is limited. Calcific stenosis of the
valve and/or accumulation of intimal peel may cause pro-
gressive obstruction of the conduit and valve regurgitation.
Therefore, those patients who have received surgically
implanted prosthetic conduits are committed to multiple
reoperations during their lifespan.
Surgically implanted conduits. During the past 10 years,
aortic and pulmonary homografts and valved conduits con-
structed from patients’ own pericardium have largely re-
placed porcine valved conduits (19). This resurgence of
aortic or pulmonary allografts, whether cryopreserved or
fresh, has not proved to be a panacea. The freedom from
reoperation remains only partially satisfactory (20). More
recently, fresh autologous pericardial valved conduits have
emerged as a possible option. These are more easily available
and have demonstrated an improved durability. In a recent
long-term follow-up study, freedom from reoperation at five
and ten years was 92% and 76%, respectively. Freedom from
reoperation at 10 years was 100% for conduits larger than 16
mm (19). Five out of 51 patients (9.8%) required a reop-
eration for conduit replacement three to eight years after the
implantation, and two had a balloon dilation for the relief of
a conduit obstruction. It appears, despite conduits’ superior
long-term durability, that degeneration is still an important
problem, and the perfect valved conduit remains elusive.
Classic interventional treatment to relief conduit steno-
sis. Percutaneous stenting of conduits has recently emerged
as an additional technique to delay the surgical replacement
of the conduit (21–25). This technique may enlarge the
stenotic conduits but, by apposing the valve within the
conduit against the wall, creates pulmonary regurgitation
that may chronically overload the RV and compromise its
long-term function. The time to the occurrence of RV
Figure 2. Echocardiography and Doppler findings before (left) and after the implantation of the bovine venous valve.
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failure as a result of pulmonary regurgitation is variable but
may depend on the existence of pulmonary hypertension or
distal pulmonary stenosis and the degree of RV hypertrophy.
Percutaneous valve insertion. We have developed a non-
surgical technique to treat conduit obstruction by replacing
the incompetent PV without compromising valve compe-
tence (6). A biological valve was harvested from a bovine
jugular vein. A section of this vein containing a tri-leaflet
valve was prepared and mounted in a stent for percutaneous
PV insertion. Sterilization and cross-linking protocols use
glutaraldehyde according to industrial standards. The high
quality of this valve has been shown in our experimental
work (6). Furthermore, the use of this valve is increasing
worldwide in surgery for congenital heart defects in humans.
Mid-term and long-term results are still missing, however.
Eight patients were included in our study protocol. All
were suffering from obstruction and/or insufficiency of the
right pulmonary outflow tract for various reasons. In all the
patients, valved stents were successfully implanted, and the
patients derived clinical benefit during the early follow-up.
The fifth patient, severely symptomatic because of RV
dysfunction and severe pulmonary regurgitation, was con-
sidered a high-risk candidate for surgery and was thus
deemed more suited to percutaneous implantation of the
valved stent. Within the first few weeks, there was an improve-
ment of the clinical status. At this stage, the recovery of RV
function is uncertain. In surgical experience, the valve replace-
ment is sometimes ineffective, and on other occasions an
improvement of symptoms and RV function may occur over a
long period of time. The non-recovery of the RV function is
generally related to irreversible myocardial damage before the
surgery or to myocardial damage of the cardiopulmonary
bypass in association with an already diseased ventricle.
Study limitations. In the present study, only valves with a
diameter of 18 mm inserted in patients with artificial RV
outflow tract were evaluated. Because the size of the whole
system is at least 18 Fr, percutaneous insertion in children
weighing less than 30 kg is delicate. Eighteen- or 20-mm
conduits are usually large enough for adults. Therefore, we
hypothesized that insertion of an 18-mm valve in such
patients would increase the lifespan of the previously in-
serted conduits and would last through adulthood. How-
ever, two major limitations should be considered. First, the
technique we propose did not remove the old PV or
dysfunctional conduit before inserting the new valve, as in a
conventional surgical procedure. Therefore, by adding a
covered stent inside the obstructed conduit, we failed to
completely relieve the obstruction in three patients. Second,
the question of the durability of the bovine jugular vein valve
remains to be answered. However, as far as degeneration is
concerned, percutaneous and surgical approaches logically
share the same inconvenience. By preserving an adequate
long-term RV function, percutaneous valve insertion may
diminish the number of surgical interventions or delay the
need for surgical conduit replacement. Valvular degenera-
tion is likely to occur in the future because of the biological
nature of the valve. In this situation, another valve may be
inserted inside the first one, similar to “Russian dolls.” Such
a technique would create some obstruction in the conduit
and would not be effective in patients without enough room
to shelter a second device.
Conclusions. Pulmonary regurgitation is generally consid-
ered clinically unimportant. Long-term studies have raised
concerns about the function of the RV. Preserving an
adequate long-term RV function therefore remains a major
challenge. We report the development and application of a
non-surgical technique to implant a PV, which may have an
important role in the management of conduit obstructions
and pulmonary regurgitation. This technique potentially
reduces the number of surgical interventions required in
patients in whom several operations may have been required
to replace malfunctioning conduits.
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